vs

Side-by-side financial comparison of Evolv Technologies Holdings, Inc. (EVLV) and RECURSION PHARMACEUTICALS, INC. (RXRX). Click either name above to swap in a different company.

Evolv Technologies Holdings, Inc. is the larger business by last-quarter revenue ($38.5M vs $35.5M, roughly 1.1× RECURSION PHARMACEUTICALS, INC.). Evolv Technologies Holdings, Inc. runs the higher net margin — 28.3% vs -304.2%, a 332.5% gap on every dollar of revenue. On growth, RECURSION PHARMACEUTICALS, INC. posted the faster year-over-year revenue change (681.7% vs 32.3%). Over the past eight quarters, RECURSION PHARMACEUTICALS, INC.'s revenue compounded faster (60.5% CAGR vs 31.8%).

Sentient Technologies was an American artificial intelligence technology company based in San Francisco. Sentient was founded in 2007 and received over $143 million in funding at different points after its inception. As of 2016, Sentient was the world's most well-funded AI company. It focused on e-commerce, online content and trading.

Recursion Pharmaceuticals is a clinical-stage biotechnology company that combines artificial intelligence and large-scale high-throughput biological experimentation to discover and develop innovative therapies for rare diseases, oncology, inflammatory disorders, and other areas of unmet medical need. It primarily operates in North America and partners with global biopharmaceutical firms to advance its robust therapeutic pipeline.

EVLV vs RXRX — Head-to-Head

Bigger by revenue
EVLV
EVLV
1.1× larger
EVLV
$38.5M
$35.5M
RXRX
Growing faster (revenue YoY)
RXRX
RXRX
+649.4% gap
RXRX
681.7%
32.3%
EVLV
Higher net margin
EVLV
EVLV
332.5% more per $
EVLV
28.3%
-304.2%
RXRX
Faster 2-yr revenue CAGR
RXRX
RXRX
Annualised
RXRX
60.5%
31.8%
EVLV

Income Statement — Q4 FY2025 vs Q4 FY2025

Metric
EVLV
EVLV
RXRX
RXRX
Revenue
$38.5M
$35.5M
Net Profit
$10.9M
$-108.1M
Gross Margin
48.4%
59.8%
Operating Margin
-20.7%
-304.8%
Net Margin
28.3%
-304.2%
Revenue YoY
32.3%
681.7%
Net Profit YoY
169.2%
39.6%
EPS (diluted)
$0.07
$-0.17

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
EVLV
EVLV
RXRX
RXRX
Q4 25
$38.5M
$35.5M
Q3 25
$42.9M
$5.2M
Q2 25
$32.5M
$19.2M
Q1 25
$32.0M
$14.7M
Q4 24
$29.1M
$4.5M
Q3 24
$27.4M
$26.1M
Q2 24
$25.2M
$14.4M
Q1 24
$22.2M
$13.8M
Net Profit
EVLV
EVLV
RXRX
RXRX
Q4 25
$10.9M
$-108.1M
Q3 25
$-1.8M
$-162.3M
Q2 25
$-40.5M
$-171.9M
Q1 25
$-1.7M
$-202.5M
Q4 24
$-15.7M
$-178.9M
Q3 24
$-30.4M
$-95.8M
Q2 24
$3.4M
$-97.5M
Q1 24
$-11.3M
$-91.4M
Gross Margin
EVLV
EVLV
RXRX
RXRX
Q4 25
48.4%
59.8%
Q3 25
49.7%
-183.8%
Q2 25
49.8%
-4.9%
Q1 25
59.8%
-48.0%
Q4 24
57.5%
-181.4%
Q3 24
57.8%
53.7%
Q2 24
58.5%
36.2%
Q1 24
54.8%
19.1%
Operating Margin
EVLV
EVLV
RXRX
RXRX
Q4 25
-20.7%
-304.8%
Q3 25
-20.1%
-3327.6%
Q2 25
-53.8%
-916.8%
Q1 25
-45.0%
-1297.9%
Q4 24
-64.9%
-4042.4%
Q3 24
-70.0%
-377.1%
Q2 24
-88.7%
-697.4%
Q1 24
-98.8%
-698.4%
Net Margin
EVLV
EVLV
RXRX
RXRX
Q4 25
28.3%
-304.2%
Q3 25
-4.2%
-3135.3%
Q2 25
-124.6%
-894.2%
Q1 25
-5.3%
-1373.3%
Q4 24
-54.0%
-3935.5%
Q3 24
-111.3%
-367.5%
Q2 24
13.6%
-676.6%
Q1 24
-50.8%
-662.4%
EPS (diluted)
EVLV
EVLV
RXRX
RXRX
Q4 25
$0.07
$-0.17
Q3 25
$-0.01
$-0.36
Q2 25
$-0.25
$-0.41
Q1 25
$-0.01
$-0.50
Q4 24
$-0.10
$-0.56
Q3 24
$-0.19
$-0.34
Q2 24
$0.02
$-0.40
Q1 24
$-0.07
$-0.39

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
EVLV
EVLV
RXRX
RXRX
Cash + ST InvestmentsLiquidity on hand
$49.1M
$743.3M
Total DebtLower is stronger
$28.6M
$9.6M
Stockholders' EquityBook value
$119.4M
$1.1B
Total Assets
$304.4M
$1.5B
Debt / EquityLower = less leverage
0.24×
0.01×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
EVLV
EVLV
RXRX
RXRX
Q4 25
$49.1M
$743.3M
Q3 25
$56.2M
$659.8M
Q2 25
$36.9M
$525.1M
Q1 25
$35.0M
$500.5M
Q4 24
$51.9M
$594.4M
Q3 24
$56.0M
$427.6M
Q2 24
$56.5M
$474.3M
Q1 24
$81.0M
$296.3M
Total Debt
EVLV
EVLV
RXRX
RXRX
Q4 25
$28.6M
$9.6M
Q3 25
$28.5M
$11.9M
Q2 25
$14.2M
Q1 25
$16.4M
Q4 24
$0
$19.0M
Q3 24
$20.5M
Q2 24
$22.9M
Q1 24
Stockholders' Equity
EVLV
EVLV
RXRX
RXRX
Q4 25
$119.4M
$1.1B
Q3 25
$102.2M
$1.0B
Q2 25
$92.7M
$919.1M
Q1 25
$121.1M
$933.9M
Q4 24
$117.7M
$1.0B
Q3 24
$129.0M
$524.6M
Q2 24
$151.2M
$584.4M
Q1 24
$139.8M
$401.2M
Total Assets
EVLV
EVLV
RXRX
RXRX
Q4 25
$304.4M
$1.5B
Q3 25
$304.3M
$1.4B
Q2 25
$280.4M
$1.3B
Q1 25
$256.0M
$1.3B
Q4 24
$268.1M
$1.4B
Q3 24
$278.5M
$726.5M
Q2 24
$269.1M
$775.9M
Q1 24
$280.0M
$557.8M
Debt / Equity
EVLV
EVLV
RXRX
RXRX
Q4 25
0.24×
0.01×
Q3 25
0.28×
0.01×
Q2 25
0.02×
Q1 25
0.02×
Q4 24
0.00×
0.02×
Q3 24
0.04×
Q2 24
0.04×
Q1 24

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
EVLV
EVLV
RXRX
RXRX
Operating Cash FlowLast quarter
$15.6M
$-46.1M
Free Cash FlowOCF − Capex
$-47.3M
FCF MarginFCF / Revenue
-133.1%
Capex IntensityCapex / Revenue
3.5%
Cash ConversionOCF / Net Profit
1.43×
TTM Free Cash FlowTrailing 4 quarters
$-378.3M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
EVLV
EVLV
RXRX
RXRX
Q4 25
$15.6M
$-46.1M
Q3 25
$3.5M
$-117.4M
Q2 25
$2.1M
$-76.4M
Q1 25
$-2.5M
$-132.0M
Q4 24
$3.2M
$-115.4M
Q3 24
$3.7M
$-59.2M
Q2 24
$-21.6M
$-82.2M
Q1 24
$-16.2M
$-102.3M
Free Cash Flow
EVLV
EVLV
RXRX
RXRX
Q4 25
$-47.3M
Q3 25
$-117.6M
Q2 25
$-79.6M
Q1 25
$-133.8M
Q4 24
$-116.7M
Q3 24
$-63.8M
Q2 24
$-83.4M
Q1 24
$-109.0M
FCF Margin
EVLV
EVLV
RXRX
RXRX
Q4 25
-133.1%
Q3 25
-2272.5%
Q2 25
-413.9%
Q1 25
-907.4%
Q4 24
-2567.7%
Q3 24
-244.6%
Q2 24
-578.5%
Q1 24
-789.9%
Capex Intensity
EVLV
EVLV
RXRX
RXRX
Q4 25
3.5%
Q3 25
4.7%
Q2 25
16.4%
Q1 25
12.4%
Q4 24
28.6%
Q3 24
17.5%
Q2 24
8.2%
Q1 24
48.2%
Cash Conversion
EVLV
EVLV
RXRX
RXRX
Q4 25
1.43×
Q3 25
Q2 25
Q1 25
Q4 24
Q3 24
Q2 24
-6.31×
Q1 24

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Related Comparisons